In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 Congress including:
- Long-term survival adjusted for treatment crossover in patients with myelofibrosis (MF) treated with momelotinib vs danazol in the MOMENTUM trial
- Efficacy of pacritinib in patients with MF who have both thrombocytopenia and anemia
- Updated safety and efficacy data from the phase III MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor–naive MF
- Impact of spleen volume on post-allogenic hematopoietic transplant outcomes in patients with MF: utility of 3D volumetrics in splenomegaly
- Progression to MF in patients with essential thrombocythemia: an analysis from the prospective MOST study
- JAK2V617F molecular response correlates with event-free survival in a patient population with early polycythemia vera
- Phase III TRANSFORM-1 study: efficacy and safety of navitoclax combined with ruxolitinib vs ruxolitinib plus placebo in patients with untreated MF
- Patient characteristics, treatment patterns, and health outcomes in a real-world population of patients with MF treated with fedratinib
Program faculty:
Brady L. Stein, MD, MHS
Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Resources:
To download the slides associated with this podcast discussion, please visit the program page.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
